by Lucence Diagnotics
A next-generation screening test for early detection of nasopharyngeal cancer (NPC) before symptoms show.
NPC GOLD™ is a cancer screening test for early stage nasopharyngeal cancer. The test detects a DNA fragment of the Epstein-Barr virus called BamHI-W, even in minute amounts, from circulating tumor DNA in blood. This virus is found in almost all patients with nasopharyngeal cancer. In Asia, nasopharyngeal cancer accounts for more than 80% of all cases in the world, with the highest prevalence in Singapore and Malaysia.
This test can also be used to monitor post treatment conditions to see if the patient is responding well to treatment. The technology has been clinically validated in a National Cancer Centre Singapore study. With NPC GOLD™, doctors will be able to detect nasopharyngeal cancer earlier and save lives earlier.
NPC GOLD™ is a cancer screening test for nose cancer. This blood test examines for the presence of DNA circulating in the blood from the Epstein Barr Virus (EBV).
If you are above 40 years of age and Asian, your risk, according to medical research studies on over 20,000 Asian individuals, is increased.
Epstein Barr Virus (EBV) is closely associated with nose cancer. Known risk factors include exposure to air pollution and a family risk of nose cancer.
NPC GOLD™ offers improved detection of nose cancer at stages 1 and 2, which allows early treatment to be effected thereby leading to increased survival rates.